Aug. 2 Quick Takes: CG Oncology raises $105M crossover round

With a Phase III study of its lead oncolytic immunotherapy cretostimogene grenadenorepvec fully enrolled, CG Oncology Inc. has raised $105 million in a series C round led by Foresite Capital and TCGX. The company will continue to conduct the Phase III BOND-003 study of its therapy for high-risk non-muscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin. Also participating in the round were Avidity Partners, BVF Partners and Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporation and RA Capital Management.

Emerson Collective has launched Yosemite, a discrete investment firm that has raised more than $200 million to make grants and venture investments with the goal of making cancer a non-lethal disease. The firm will manage prior heathcare investments by Emerson Collective, whose president is Laurene Powell Jobs, the widow of Steve Jobs; the firm’s managing director for health is Reed Jobs, the couple’s son. Limited partners in Yosemite include endowments, hospital systems and family offices, including The Rockefeller University, Memorial Sloan Kettering Cancer Center and John Doerr. ...